Switzerland’s Actelion has unveiled a profitable set of figures which reveal a sizeable cash pile, though sales of its lead drug Tracleer slowed down from the previous quarter.
Read MoreGlaxoSmithKline has once again hit the acquisition trail and snapped up Sirtris Pharmaceuticals of the USA for $720 million, or $22.50 per share, a cash deal that represents a massive 84% premium on the latter’s stock price last night.
Read MoreGermany’s Merck KGaA says that first-quarter operating profit leapt 49.3% to 359.6 million euros, boosted by strong sales of the cancer drug Erbitux and the multiple sclerosis treatment Rebif.
Read MoreWyeth has posted a solid set of financials for the first quarter especially given the sales decline suffered by its antiulcerant blockbuster Protonix as generic competition kicks in.
Read MoreUS regulators have sent a warning letter to Pfizer about a promotional video for Viagra which failed to point out the risks involved in taking the erectile dysfunction blockbuster.
Read More
